SecBot SecBot
SECBOTREPLAY Home › Report › TEVA

TEVA · Teva reported Q2 2026 revenue of $4.14B (-1% YoY) and non-GAAP EPS of…

TEVA PHARMACEUTICAL INDUSTRIES LTD · 8-K filed Jul 29, 2026 at 07:00 ET

At the news

MIXEDIMPACT 5/10

8-K filed Jul 29, 2026 at 07:00 ET

Teva reported Q2 2026 revenue of $4.14B (-1% YoY) and non-GAAP EPS of $0.02, both below consensus ($0.05). The headline GAAP loss of $0.49/share was driven by a $726M Emalex acquisition charge ($724M IPR&D). However, key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 43% YoY in local currency to over $1B, and the company raised its 2026 revenue outlook for all three brands. Full-year non-GAAP EPS guidance of $1.91-$2.11 was maintained, implying a strong H2 ramp. A credit rating upgrade to investment-grade BBB- by Fitch and the planned ADS-to-direct-listing conversion add to the positive narrative.

  • Q2 2026 revenue $4,142M, down 1% YoY ($4,176M) and 3% in local currency
  • GAAP loss per share $0.49 vs $0.24 EPS in Q2 2025; includes $726M Emalex-related expenses
  • Non-GAAP diluted EPS $0.02 vs $0.66 a year ago, also impacted by ($0.61)/share from Emalex
  • Key innovative brands (AUSTEDO $696M, AJOVY $244M, UZEDY $77M) grew 43% LC YoY; 2026 revenue outlook raised to ~$3.7B combined

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access